Bellerophon Therapeutics, Inc.·4

Dec 13, 5:25 PM ET

Laccona Nicholas 4

4 · Bellerophon Therapeutics, Inc. · Filed Dec 13, 2022

Insider Transaction Report

Form 4
Period: 2022-12-09
Laccona Nicholas
Controller, (PFO & PAO)
Transactions
  • Tax Payment

    Common Stock

    2022-12-09$0.93/sh5,530$5,14312,470 total
  • Exercise/Conversion

    Common Stock

    2022-12-09+18,00018,000 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-12-0918,00018,000 total
    Common Stock (18,000 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit represents the contingent right to receive, upon vesting of the unit, one share of Bellerophon common stock.
  • [F2]On January 26, 2022, the reporting person was granted 36,000 restricted stock units, 50% vesting on December 9, 2022 and 50% vesting on December 8, 2023, as long as the reporting person remains in the service of Bellerophon through the respective vesting date.

Documents

1 file
  • 4
    form4-12132022_051201.xmlPrimary